Stay updated with breaking news from Monograph Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational
Lumira Ventures Announces Investment in Nocion Therapeutics to Revolutionize ...